Matinas BioPharma to Present at the 27th Annual ROTH Conference on March 11, 2015

Live Presentation With Audio Webcast on Wednesday, March 11th at 11:30 a.m. Pacific Time / 2:30 p.m. Eastern Time

BEDMINSTER, N.J., March 4, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (Matinas BioPharma or the Company) (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of lipid-based prescription therapeutics for the treatment of fungal and bacterial infections, as well as metabolic/cardiovascular conditions, announced today that it will be presenting at the the 27th Annual ROTH Conference being held March 8-11, 2015, at The Ritz-Carlton, Laguna Niguel, in Dana Point, California.

Roelof Rongen, President and Chief Executive Officer, will present on Wednesday, March 11, 2015 at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time). Mr. Rongen will provide an overview of the Company's lead product candidates, MAT2203, a novel lipid-crystal nano-particle delivered formulation of Amphotericin B for the treatment of invasive fungal infections, and MAT9001, a prescription-only omega-3 fatty acid-based composition specifically designed for the treatment of severe hypertriglyceridemia.

Mr. Rongen will also discuss the plans for the Company's earlier stage development programs, MAT2501, a lipid-crystal nano-particle delivered formulation of Amikacin for the treatment of gram-negative bacterial infections, and MAT8800, a proprietary omega-3 discovery program for the treatment of fatty liver disease.

A live audio webcast of the presentation will be available on the Events page of the Investor Relations section of the Company's website (www.matinasbiopharma.com). A webcast replay will be available approximately two hours after the presentation ends and will be accessible for one month.

About Matinas BioPharma

Matinas BioPharma is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel lipid-based pharmaceutical products for the treatment of fungal and bacterial infections and cardiovascular and metabolic conditions. Led by an experienced management team and a board of directors with a history of building pharmaceutical companies, Matinas is focused on creating highly differentiated, safe and efficacious therapies utilizing its expertise in drug formulation and development in order to address significant unmet medical needs. Recent additions to its product pipeline, including MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulations.

For more information, please visit www.matinasbiopharma.com and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.

Forward Looking Statements: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.

CONTACT: Investor and Media Contact
         Jenene Thomas
         Investor Relations and Corporate Communications Advisor
         Jenene Thomas Communications, LLC
         Phone: +1 (908) 938-1475
         Email: jthomas@matinasbiopharma.com

Released March 4, 2015